Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.
A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.
Lee
M S
MS
Department of Neurology, Yongdong Severance Hospital, Yonsei University College of Medicine, South Korea.
Lyoo
C H
CH
Ulmanen
I
I
Syvänen
A C
AC
Rinne
J O
JO
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D007723:Korea; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000188:drug therapy / Q000235:genetics; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
D000978:Antiparkinson Agents; D007980:Levodopa; D002394:Catechol O-Methyltransferase